Bioequivalence in Healthy Subjects Clinical Trial
The aim of this study is to assess the bioequivalence of two premixed formulations of insulin Lispro, Humalog Mix50/50® and ListroMix 50/50® in healthy subjects based on the pharmacokinetic parameter (PK) and the pharmacodynamic parameter (PD).
The primary objective of this study is assess the bioequivalence of two premixed formulations of insulin Lispro, Humalog Mix50/50® and ListroMix 50/50® in healthy subjects based on the pharmacokinetic parameter (PK) AUC (INS-LIS 0-20h) and the pharmacodynamic parameter (PD) AUC (GIR 0-20h) and also assess the safety and local tolerability of the two insulin preparations. ;
Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Health Services Research
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT01400802 -
Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects
|
Phase 1 | |
| Withdrawn |
NCT01399255 -
Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Lispro (Listroâ„¢) With Humalog® in Healthy Subjects
|
Phase 1 |